Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Should Biosimilars Be Cheap? Sponsors Aren't So Sure

Executive Summary

Policymakers often frame the value of biosimilars in terms of how inexpensive they are, but sponsors use arguments that resemble those of their innovator counterparts. 
Advertisement

Related Content

VA Changes Infliximab Biosimilars; Merck Formulary Win Could Drive Questions On Patient Switching
VA Changes Infliximab Biosimilars; Merck Formulary Win Could Drive Questions On Patient Switching
Enthusiasm For US Biosimilars Wanes For Some, But Not Others
Biosimilars Need Better Reimbursement, Not 'Kabuki' Coverage, Gottlieb Tells Insurers
Payers Like Biosimilars, But Rebates Remain The Bottom Line (For Now)

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS123825

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel